Regulus Therapeutics Inc.
Regulus Therapeutics Inc. (Form: SC 13G/A, Received: 08/09/2017 17:03:25)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)*

 

 

Regulus Therapeutics Inc.

(Name of Issuer)

COMMON STOCK, $0.001 PAR VALUE PER SHARE

(Title of Class of Securities)

75915K101

(CUSIP Number)

March 24, 2017 (1)

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(1) The reporting person is not required to amend its Schedule 13G filing until after the end of the 2017 calendar year. However, the reporting person has elected to voluntarily amend its Schedule 13G filing at this time to reflect its current beneficial ownership.

 

 

 


CUSIP No. 75915K101  

 

  1.   

NAMES OF REPORTING PERSONS

 

Alnylam Pharmaceuticals, Inc.

  2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)  ☐        (b)  ☐

 

  3.  

SEC USE ONLY

 

  4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

   5.    

SOLE VOTING POWER

 

0

   6.   

SHARED VOTING POWER

 

0

   7.   

SOLE DISPOSITIVE POWER

 

0

   8.   

SHARED DISPOSITIVE POWER

 

0

  9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0

10.  

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0%

12.  

TYPE OF REPORTING PERSON

 

CO

 

Page 2 of 5 Pages


CUSIP No. 75915K101

 

Item 1.       Issuer
   (a)    Name of Issuer:
      Regulus Therapeutics Inc. (the “ Issuer ”)
   (b)    Address of Issuer’s Principal Executive Offices:
     

10614 Science Center Dr.

San Diego, CA 92121

Item 2.       Filing Person
   (a) – (c)    Name of Person Filing; Address; Citizenship:
     

Alnylam Pharmaceuticals, Inc., a Delaware corporation

 

The address of the principal business office of the reporting person is 300 Third Street, 3 rd Floor, Cambridge, MA 02142.

   (d)    Title of Class of Securities:
      Common stock, $0.001 par value per share
   (e)   

CUSIP Number:

 

75915K101

Item 3.       Description of Person Filing
      Not applicable.

 

Page 3 of 5 Pages


CUSIP No. 75915K101

 

Item 4.    Ownership.
   (a) and (b)    Amount beneficially owned; percent of class:
     

The reporting person directly owns 0 shares, which represents approximately 0% of the outstanding shares of common stock.

   (c)    Number of shares as to which such person has:
  

(i)     Sole power to vote or direct the vote

 

0 shares

 

(ii)    Shared power to vote or to direct the vote

 

0 shares

 

(iii)  Sole power to dispose or to direct the disposition of

 

0 shares

 

(iv)   Shared power to dispose or to direct the disposition of

 

0 shares

 

Item 5.   

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

 

Based on 52,932,405 shares of the Issuer’s common stock outstanding as of February 24, 2017, as disclosed by the Issuer in its Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 3, 2017, the reporting person ceased to be the beneficial owner of more than five percent of the class of securities as of March 24, 2017.

 

The reporting person is not required to amend its Schedule 13G filing until after the end of the 2017 calendar year. However, the reporting person has elected to voluntarily amend its Schedule 13G filing at this time to reflect its current beneficial ownership.

Item 6.   

Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

Item 7.   

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable.

Item 8.   

Identification and Classification of Members of the Group.

 

Not applicable.

Item 9.   

Notice of Dissolution of Group.

 

Not applicable.

Item 10.   

Certification.

 

Not applicable.

 

Page 4 of 5 Pages


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 9, 2017

 

ALNYLAM PHARMACEUTICALS, INC.
      By:  

/s/ Michael P. Mason

  Michael P. Mason
  Vice President, Finance and Treasurer

 

Page 5 of 5 Pages